SCHEMBL720219

SCHEMBL720219

Cc1cc(I)cc(C)c1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 2/20 0.58
CA1 P00915 1/20 0.58
CA2 P00918 1/20 0.58
GABRA1 P14867 1/20 0.46
GABRB1 P18505 1/20 0.46
GABRB2 P47870 1/20 0.46
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44
ALDH1A1 P00352 2/20 0.43
GAA P10253 2/20 0.40
KDM4E B2RXH2 2/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 2/20 0.40
PTGS1 P23219 5/20 0.39
PTGS2 P35354 5/20 0.39
ALOX5 P09917 4/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7873607 0.88 TTR (0.78) TTRCA1CA2GABRA1GABRB1
SCHEMBL18709223 0.78 EGFR (0.46) TTRCA1CA2GAALMNA
SCHEMBL2321159 0.77 HMGB1 (0.58) TTRALDH1A1GAAKDM4EMAPT
SCHEMBL20799740 0.77 TTR (0.41) TTRCA1CA2GABRA1GABRB1
SCHEMBL9516157 0.77 TTR (0.41) TTRCA1CA2GABRA1GABRB1
SCHEMBL2925311 0.77 ERN1 (0.64) TTRCA1CA2ALDH1A1
SCHEMBL24170744 0.75 TTR (0.39) TTRCA1CA2GABRA1GABRB1
SCHEMBL11867319 0.75 TTR (0.39) TTRCA1CA2GABRA1GABRB1
SCHEMBL2171725 0.75 TTR (0.43) TTRCA1CA2GABRA1GABRB1
SCHEMBL16790391 0.75 CA1 (0.74) TTRCA1CA2ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117844226-A Polyphenyl ether composite material, and preparation method and application thereof 深圳烯湾科技有限公司 2024-04-09 CN claimed
CN-117129594-A Method for measuring total inorganic iodine in water body 天津大学 2023-11-28 CN claimed
CN-117129593-A Method for simply and effectively measuring concentration of iodide ions 天津大学 2023-11-28 CN claimed
CN-109369623-B Substituted 1,2,3 triazole diaryl pyrimidine derivative and preparation method and application thereof 山东大学 2020-04-21 CN claimed
CN-109369623-A 1,2,3 triazole diaryl pyrimidine derivatives of a kind of substitution and the preparation method and application thereof 山东大学 2019-02-22 CN claimed
EP-1066269-B1 TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS JANSSEN PHARMACEUTICA NV (BE) 2005-05-11 EP claimed
US-20020115668-A1 Trisubstituted 1,3,5-triazine derivatives DAEYAERT FREDERIK FRANS DESIRE (BE) 2002-08-22 US claimed
CN-1330679-A Plastic moulding materials which can be detected by x-ray contrast BAYER AG (DE) 2002-01-09 CN claimed
EP-1066269-A1 TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS JANSSEN PHARMACEUTICA N.V. (BE) 2001-01-10 EP claimed
US-6150360-A ADMINISTERING TO A PATIENT SUFFERING FROM HUMAN IMMUNODEFICIENCY VIRUS INFECTION A TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVE JANSSEN PHARMACEUTICA N.V. (BE) 2000-11-21 US claimed
WO-1999050256-A1 TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS JANSSEN PHARMACEUTICA N.V. (BE) 1999-10-07 WO claimed
US-20250205232-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-06-26 US disclosed
CN-116135858-B Furanopyridone compound and application thereof 中国科学院广州生物医药与健康研究院 2025-04-01 CN disclosed
WO-2025041679-A1 COMPOUND, COMPOSITION, CURED PRODUCT, OPTICALLY ANISOTROPIC BODY, OPTICAL ELEMENT, AND LIGHT GUIDE ELEMENT 富士フイルム株式会社 2025-02-27 WO disclosed
US-12168009-B2 Modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-12-17 US disclosed
WO-1999050256-A1 TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS JANSSEN PHARMACEUTICA N.V. (BE) 1999-10-07 WO disclosed
EP-0207453-B1 Heterocyclic substituted-phenoxyalkyl-isoxazoles and-furans, their preparation and use as antiviral agents STERLING WINTHROP INC (US) 1994-06-22 EP disclosed
EP-0377638-B1 PROCESS FOR THE IODINATION OF HYDROXYAROMATIC AND AMINOAROMATIC COMPOUNDS EASTMAN KODAK COMPANY (US) 1993-03-24 EP disclosed
US-4857539-A Heterocyclic substituted-phenoxyalkylisoxazoles as antiviral useful agents STERLING DRUG INC. (US) 1989-08-15 US disclosed
EP-0207453-A2 Heterocyclic substituted-phenoxyalkyl-isoxazoles and-furans, their preparation and use as antiviral agents STERLING WINTHROP INC. (US) 1987-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115668-A1 Trisubstituted 1,3,5-triazine derivatives XDH, CCR5, CXCR1 TTR 2164/4885CA1 4799/4885CA2 4527/4885
US-20250205232-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1B, SLC26A4 TTR 4454/4885CA1 4843/4885CA2 1067/4885
US-12168009-B2 Modulators of cystic fibrosis transmembrane conductance regulator CFTR, SCNN1B, SLC26A4 TTR 4454/4885CA1 4843/4885CA2 1067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.